Special Issue "Marine Bioactive Compounds with Neuroprotective Potential"
A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".
Deadline for manuscript submissions: 31 January 2024 | Viewed by 88
Special Issue Editor
Interests: cells of the immune system; the molecular mechanism of action; membrane receptors; neurodegenerative disorders; cytoptotection; inflammation; new drug discovery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neurodegenerative disorders are the second leading cause of death worldwide and the first leading cause of disability. The most common diseases affecting the brain are Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis. Due to the high mortality and incidence of neurological disorders, preventive and therapeutic strategies are critical. Currently, no effective pharmacological treatment has been proposed that would block or treat the progression of neurodegenerative diseases. Conventional medications prescribed to treat neurological disorders are associated with various side effects; consequently, in recent years, many researchers have considered the possible therapeutic effects of natural products on neurological diseases. The search and development of new approaches and drugs for their treatment is an extremely urgent task. In recent years, natural compounds of marine origin have been of great interest for their structural diversity and wide range of biological activity. In addition to antioxidant, anti-inflammatory, antiproliferative, antidiabetic, and cardioprotective properties, biocompounds of a marine origin have also shown neuroprotective activity.
Thus, through the utilization of the biological functions of the most intensively studied biocompounds as potential drugs for neurodegenerative disorders, marine pharmacology is constantly proving its potential in the field of biomedicine.
This Special Issue is intended to present ongoing research into the neuroprotective properties of marine natural compounds. We particularly welcome papers evaluating the molecular mechanisms of action of marine-derived compounds and their analogues. Also of interest are works on the isolation and structure determination of new compounds of marine origin with neuroprotective activity in the latest in vitro and in vivo models in the field of neurodegenerative disease research.
Dr. Evgeny A. Pisliagin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- new drug discovery and development
- neuroinflammation
- neurodegenerative diseases
- marine biologically active compounds
- neuroprotection
- central nervous system (CNS) disorders
- Alzheimer’s disease (AD)
- Parkinson’s disease (PD)
- schizophrenia
- dementia
